The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Introduction to current and future protein therapeutics: A protein engineering perspective
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“For example, several anti-cancer antibodies provide an overall survival benefit, including bevacizumab [42] and trastuzumab [43] in combination with chemotherapy in metastatic colorectal and breast cancers, respectively.”
BackgroundBevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Network medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161 · cited 2×
“, interferon-α, tissue plasminogen activator, and erythropoietin) [2].”
BackgroundTherapeutic antibodies: successes, limitations and hopes for the future
Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00190.x · Cited by 1,382
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero-Torres, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002965 · Cited by 1,368
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Self-citationTumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078
The Impact of PEGylation on Biological Therapies
Veronese, F. M., & Mero, A. (2008) · BioDrugs · doi:10.2165/00063030-200822050-00004 · Cited by 1,034
Assembly of a Functional Immunoglobulin F v Fragment in Escherichia coli
Skerra, A., & Plückthun, A. (1988) · Science · doi:10.1126/science.3285470 · Cited by 978
Expression in Escherichia coli of chemically synthesized genes for human insulin.
Goeddel, D. V., Kleid, D. G., Bolivar, F., Heyneker, H. L., Yansura, D. G., Crea, R., Hirose, T., Kraszewski, A., Itakura, K., & Riggs, A. D. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.1.106 · Cited by 869
Strategies and challenges for the next generation of therapeutic antibodies
Beck, A., Wurch, T., Bailly, C., & Corvaia, N. (2010) · Nature Reviews Immunology · doi:10.1038/nri2747 · Cited by 847
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
Self-citationBiopharmaceutical benchmarks 2010
Walsh, G. (2010) · Nature Biotechnology · doi:10.1038/nbt0910-917 · Cited by 756
Thrombocytopenia caused by the development of antibodies to thrombopoietin
Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M., & Kuter, D. J. (2001) · Blood · doi:10.1182/blood.v98.12.3241 · Cited by 683
PEGylation of therapeutic proteins
Jevševar, S., Kunstelj, M., & Porekar, V. G. (2010) · Biotechnology Journal · doi:10.1002/biot.200900218 · Cited by 681
Engineering novel binding proteins from nonimmunoglobulin domains
Binz, H. K., Amstutz, P., & Plückthun, A. (2005) · Nature Biotechnology · doi:10.1038/nbt1127 · Cited by 676
Industrialization of mAb production technology: The bioprocessing industry at a crossroads
Kelley, B. (2009) · mAbs · doi:10.4161/mabs.1.5.9448 · Cited by 667
Antibody–drug conjugates: targeted drug delivery for cancer
Alley, S. C., Okeley, N. M., & Senter, P. D. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.170 · Cited by 656
Enhanced antibody half-life improves in vivo activity
Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I. W. L., Sproule, T. J., Lazar, G. A., Roopenian, D. C., & Desjarlais, J. R. (2010) · Nature Biotechnology · doi:10.1038/nbt.1601 · Cited by 653
Designing CD4 immunoadhesins for AIDS therapy
Capon, D. J., Chamow, S. M., Mordenti, J., Marsters, S. A., Gregory, T., Mitsuya, H., Byrn, R. A., Lucas, C., Wurm, F. M., Groopman, J. E., et al. (1989) · Nature · doi:10.1038/337525a0 · Cited by 615
Escherichia coli Secretion of an Active Chimeric Antibody Fragment
Better, M., Chang, C. P., Robinson, R. R., & Horwitz, A. H. (1988) · Science · doi:10.1126/science.3285471 · Cited by 579
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Schmidt, M. M., & Wittrup, K. D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0195 · Cited by 576
From the bench to the bedside: ways to improve rituximab efficacy
Cartron, G., Watier, H., Golay, J., & Solal-Celigny, P. (2004) · Blood · doi:10.1182/blood-2004-03-1110 · Cited by 523
Enhancement of therapeutic protein in vivo activities through glycoengineering
Elliott, S., Lorenzini, T., Asher, S., Aoki, K., Brankow, D., Buck, L., Busse, L., Chang, D., Fuller, J., Grant, J., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt799 · Cited by 510
Glycosylation of Therapeutic Proteins: An Effective Strategy to Optimize Efficacy
Solá, R. J., & Griebenow, K. (2010) · BioDrugs · doi:10.2165/11530550-000000000-00000 · Cited by 440
Antibody-Drug Conjugates for Cancer Therapy
Carter, P. J., & Senter, P. D. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318172d704 · Cited by 429
Self-citationIgawa, T., Ishii, S., Tachibana, T., Maeda, A., Higuchi, Y., Shimaoka, S., Moriyama, C., Watanabe, T., Takubo, R., Doi, Y., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1691 · Cited by 353
Therapeutic antibody fragments with prolonged in vivo half-lives
Chapman, A. P., Antoniw, P., Spitali, M., West, S., Stephens, S., & King, D. J. (1999) · Nature Biotechnology · doi:10.1038/11717 · Cited by 350
Engineered protein scaffolds as next-generation antibody therapeutics
Gebauer, M., & Skerra, A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.04.627 · Cited by 341
High Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody Fragment
Carter, P., Kelley, R. F., Rodrigues, M. L., Snedecor, B., Covarrubias, M., Velligan, M. D., Wong, W. L. T., Rowland, A. M., Kotts, C. E., Carver, M. E., et al. (1992) · Nature Biotechnology · doi:10.1038/nbt0292-163 · Cited by 330
Self-citationBendele, A. M., Seely, J., Richey, C., Sennello, G., & Shopp, G. M. (1998) · Toxicological Sciences · doi:10.1006/toxs.1997.2396 · Cited by 279
Catumaxomab: Clinical development and future directions
Linke, R., Klein, A., & Seimetz, D. (2010) · mAbs · doi:10.4161/mabs.2.2.11221 · Cited by 274
Monoclonal Antibodies as Innovative Therapeutics
Reichert, J. (2008) · Current Pharmaceutical Biotechnology · doi:10.2174/138920108786786358 · Cited by 265
Molecular engineering and design of therapeutic antibodies
Presta, L. G. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.012 · Cited by 250
Strategies to Extend Plasma Half-Lives of Recombinant Antibodies
Kontermann, R. E. (2009) · BioDrugs · doi:10.2165/00063030-200923020-00003 · Cited by 243
Increasing the serum persistence of an IgG fragment by random mutagenesis
Ghetie, V., Popov, S., Borvak, J., Radu, C., Matesoi, D., Medesan, C., Ober, R. J., & Ward, E. S. (1997) · Nature Biotechnology · doi:10.1038/nbt0797-637 · Cited by 241
Almagro, J. C., & Fransson, J. (2008) · PubMed · doi:10.2741/2786 · Cited by 220
Network Systems Biology for Drug Discovery
Arrell, D. K., & Terzic, A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.91 · Cited by 217
Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs
Holt, L. J., Basran, A., Jones, K., Chorlton, J., Jespers, L. S., Brewis, N. D., & Tomlinson, I. M. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzm067 · Cited by 193
Fully human antibodies from transgenic mouse and phage display platforms
Lonberg, N. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.004 · Cited by 188
Engineered therapeutic antibodies with improved effector functions
Kubota, T., Niwa, R., Satoh, M., Akinaga, S., Shitara, K., & Hanai, N. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01222.x · Cited by 168
Receptor-Fc fusion therapeutics, traps, and MIMETIBODY™ technology
Huang, C. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.010 · Cited by 166
Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier
Lampson, L. A. (2011) · mAbs · doi:10.4161/mabs.3.2.14239 · Cited by 152
Targeting antibodies to the cytoplasm
Marschall, A. L. J., Frenzel, A., Schirrmann, T., Schüngel, M., & Dübel, S. (2011) · mAbs · doi:10.4161/mabs.3.1.14110 · Cited by 120
Fc-Based Cytokines: Prospects for Engineering Superior Therapeutics
Jazayeri, J. A., & Carroll, G. J. (2008) · BioDrugs · doi:10.2165/00063030-200822010-00002 · Cited by 113
Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids
Ackerman, M. E., Pawlowski, D., & Wittrup, K. D. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0067 · Cited by 107
Reichert, J. M. (2010) · mAbs · doi:10.4161/mabs.2.1.10677 · Cited by 106
Human Monoclonal Antibodies from Transgenic Mice
Lönberg, N. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_4 · Cited by 105
Display scaffolds: protein engineering for novel therapeutics
Nuttall, S. D., & WALSH, R. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.007 · Cited by 87
Recombinant approaches to IgG-like bispecific antibodies
Marvin, J. S., & Zhu, Z. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00119.x · Cited by 87
Biosimilars – Science, status, and strategic perspective
Kresse, G. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.02.014 · Cited by 86
Metrics for antibody therapeutics development
Reichert, J. M. (2010) · mAbs · doi:10.4161/mabs.2.6.13603 · Cited by 85
Insulin and its analogs: actions via insulin and IGF receptors
Vigneri, R., Squatrito, S., & Sciacca, L. (2010) · Acta Diabetologica · doi:10.1007/s00592-010-0215-3 · Cited by 71
Insulin analog therapy: improving the match with physiologic insulin secretion.
Freeman, J. S. (2009) · PubMed · Cited by 67
Walker, A. R., Dunlevy, G., Rycroft, D., Topley, P., Holt, L. J., Herbert, T., Davies, M. L., Cook, F., Holmes, S., Jespers, L. S., et al. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzp091 · Cited by 67
Niculescu‐Duvaz, I. (2010) · PubMed · Cited by 65
Kiss, Z., Elliott, S. G., Jedynasty, K., Tesař, V., & Szegedi, J. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0780-y · Cited by 61
Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies.
Norman, D. J., Chatenoud, L., Cohen, D., Goldman, M., & Shield, C. F. (1993) · PubMed · Cited by 50
Zuraw, B. L., Yasothan, U., & Kirkpatrick, P. N. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3125 · Cited by 45
Advances in targeted therapeutic agents
Nicolaides, N. C., Sass, P. M., & Grasso, L. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2010.521496 · Cited by 36
Cited by
The CamSol method of rational design of protein mutants with enhanced solubility
Sormanni, P., Aprile, F. A., & Vendruscolo, M. (2015) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.09.026 · Cited by 494
Recent advances in (therapeutic protein) drug development
Lagassé, H. A. D., Alexaki, A., Simhadri, V. L., Katagiri, N. H., Jankowski, W., Sauna, Z. E., & Kimchi-Sarfaty, C. (2017) · F1000Research · doi:10.12688/f1000research.9970.1 · Cited by 481
“for dermatology (3), gastroenterology (2), obstetrics/gynecology (2), pediatrics (1), pulmonary/respiratory disease (1), and urology (1) (Figure 2c, right).”
BackgroundFc‐fusion proteins: new developments and future perspectives
Czajkowsky, D. M., Hu, J., Shao, Z., & Pleass, R. J. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201379 · Cited by 476
Progress in biopharmaceutical development
Kesik‐Brodacka, M. (2018) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1617 · Cited by 353
Dimitrov, D. S. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-921-1_1 · Cited by 347
Metadata
- Authors
- Carter, P. J.
- Venue
- Experimental Cell Research
- Publisher
- Elsevier BV
- Published
- 2011-05
- Volume
- 317
- Issue
- 9
- Pages
- 1261-1269
- ISSN
- 0014-4827 (ISSN-L)
- OpenAlex
- W2025629542
- Cited by
- 467
- References
- 63
- FWCI
- 27.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.